Ascendis Pharma A/S Announces Planned Board Transition
Share: – Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM – COPENHAGEN, Denmark, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 Annual General Meeting (AGM). Michael Wolf Jensen informed the Board of Directors (the Board)...
Source: benzinga.com